✓ Translated by DotMD AI Clinical Council Source: Journal of the American Academy of Dermatology • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #17761356 ↗

Randomized Controlled Trial: A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men

Original Paper Title: “A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • We believe that 5% MTF is a safe and effective treatment for men with AGA.
  • Study Design & Sample: Randomized Controlled Trial published in Journal of the American Academy of Dermatology (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of the American Academy of Dermatology (2007), this randomized controlled trial evaluating human clinical outcomes investigated: An alternative to currently marketed topical minoxidil solutions is desirable. Key clinical takeaway: We believe that 5% MTF is a safe and effective treatment for men with AGA.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of the American Academy of Dermatology, 2007-11-15; Randomized Controlled Trial; Rigor 88/100): We believe that 5% MTF is a safe and effective treatment for men with AGA.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: minoxidil → Rx: stay-minoxidil-hair-regrowth-treatment-minoxidil-5 → Condition: other-androgenic-alopecia → Condition: anagen-effluvium →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 17761356: Randomized Controlled Trial: A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men

3 of 3 Free Questions Remaining